secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quoin Pharmaceuticals, Ltd. (QNRX)
CIK:        0001671502
Form:       8-K
Filed at:   2025-10-15T23:59:59+00:00
Accession:  0001104659-25-099735
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Quoin raises $16.6M upfront in PIPE; up to $104.6M total with milestone warrants
--------------------------------------------------------------------------------

- Upfront gross proceeds of $16.6M ($15M net) from private placement; proceeds for QRX003 development and general corporate.
- Warrant series H, I, J, K with exercise prices $9.075-$12.375 per ADS; potential cash proceeds up to $88M if exercised.
- Investors include AIGH Capital, Soleus Capital, Nantahala Capital, Diadema, Stonepine, ADAR1, Velan; director Langer invested $128k.
- Warrant exercise triggers tied to FDA milestones for QRX003: Type C meeting, pivotal trial endpoints, FDA approval, or PRV sale.
- Directors and officers subject to 180-day lock-up; proceeds with warrant exercise expected to fund operations into 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671502/000110465925099735/0001104659-25-099735-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671502/000110465925099735/tm2528687d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-099735

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer